A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
D Clement - Lancet, 1996 - biblio.ugent.be
Background Many clinical trials have evaluated the benefit of long-term use of antiplatelet
drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been …
drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been …
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
CAPRIE Steering Committee - The Lancet, 1996 - Elsevier
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
M Dennis, CAPRIE Steering Committee - The Lancet, 1996 - research.ed.ac.uk
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …
Results of the CAPRIE trial: efficacy and safety of clopidogrel
MA Creager - Vascular Medicine, 1998 - journals.sagepub.com
The recent CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events)
compared clopidogrel with aspirin in reducing the risk of vascular events in 19 185 patients …
compared clopidogrel with aspirin in reducing the risk of vascular events in 19 185 patients …
Clopidogrel: a review of its use in the prevention of thrombosis
GL Plosker, KA Lyseng-Williamson - Drugs, 2007 - Springer
Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …
Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel
PB Gorelick, GVR Born, RB D'Agostino, DF Hanley Jr… - Stroke, 1999 - Am Heart Assoc
Background—Antiplatelet agents are widely recognized for their efficacy in reducing the
occurrence of vascular events in patients with atherothrombotic disease. Aspirin is currently …
occurrence of vascular events in patients with atherothrombotic disease. Aspirin is currently …
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High …
BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …
studied in a broad population of patients at high risk for atherothrombotic events. Methods …
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
COMMIT (ClOpidogrel and Metoprolol in Myocardial … - The Lancet, 2005 - thelancet.com
Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double …
HC Diener, J Bogousslavsky, LM Brass, C Cimminiello… - The Lancet, 2004 - thelancet.com
Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …